Open an account

Indivior Pharmaceuticals

INDV · NASDAQ

$34.77+$0.90 (+2.66%)TodayMarket closed ·
Prev close $33.87

About INDV

Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The firm provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The company sells its products in the United States and in other selected areas of the world.

Employees
827
Headquarters
SLOUGH, Virginia
Listed
Jun 12, 2023
Sector
Health Care
Industry
Pharmaceuticals
Website
indivior.com

INDV key statistics

Market cap
4.10B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.46M
Volume
1.93M
Open price
$34.02
High today
$35.12
Low today
$33.80
52 Week high
$42.81
52 Week low
$23.72

Indivior Pharmaceuticals (INDV) at a glance

Indivior Pharmaceuticals (INDV) last traded at $34.77, with a market cap of 4.10B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $33.80 and $35.12. The current price is 2.9% above the day's low and 1.0% below its high.

Volume so far is 1.93M shares, below the average of 2.46M shares a day.

Over the past year Indivior Pharmaceuticals has ranged from $23.72 to $42.81, and now sits 58% of the way up that range.

Indivior Pharmaceuticals met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported $1.15 per share against an estimate of $0.8917.

The average analyst price target is $49.98, 43.7% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $49.98
Low
$43.43
Now
$34.77
High
$55.65

INDV earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 55.6% on average.

  1. Q3 FY24: reported $0.54 per share against an estimate of $0.3162
  2. Q4 FY24: reported $0.32 per share against an estimate of $0.2193
  3. Q1 FY25: reported $0.41 per share against an estimate of $0.238
  4. Q2 FY25: reported $0.51 per share against an estimate of $0.2652
  5. Q3 FY25: reported $0.72 per share against an estimate of $0.4199
  6. Q4 FY25: reported $0.82 per share against an estimate of $0.6875
  7. Q1 FY26: reported $0.96 per share against an estimate of $0.6681
  8. Q2 FY26: reported $1.15 per share against an estimate of $0.8917

INDV news

  • Press releasePRNewswire

    Are LFCR, ITGR, FHB, INDV Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    ACT NOW - The M&A Class Action Firm Is Investigating the Merger -- FHB, INDV, ITGR, and LNTH

  • Press releaseBusiness Wire

    Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

  • Press releaseBusiness Wire

    INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

  • Press releaseBusiness Wire

    Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV)

  • Vandana Singh

    Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue

  • Press releaseBusiness Wire

    INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

Similar companies

Companies in the same industry as Indivior Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.